Founded in March 2012, the company is located in Guangzhou Science City High Tech Industrial Development Zone. It is mainly engaged in the research and development of innovative drugs for the treatment of cancer and other serious diseases. The company's founder and chairman, Dr. Changgeng Qian, is one of the “1000 Talents Plan” experts in China. Prior to returning to China, Dr. Qian was the Senior Vice President in charge of new drug development at Curis, a Nasdaq listed pharmaceutical company in Boston, MA, USA. The company’s board of directors and management team consists of top scientists and executives with years of US pharmaceutical industry experience, advanced university research expertise, and outstanding management skills. Among them are 9 PhDs and 2 experts who are among awardees of the prestigious national“Thousand Talents Plan”of the Chinese government.

    The company has strong expertise and outstanding facilities to conduct comprehensive pharmaceutical research that includes chemical synthesis, new pharmaceutical lead identification, preclinical research, and clinical evaluation.
The company's leading anti-cancer drug candidate, BEBT-908 is currently undergoing phase I clinical trial in China. BEBT-908 is an HDAC/PI3K dual inhibitor with a first-in-class structure. It can attack and disrupt both HDAC and PI3K signaling pathways simultaneously and with extremely high potency. In preclinical studies, it has demonstrated impressive activities against lymphoma, myeloma, and leukemia; causing tumor regression in animal models.  As the number of newly diagnosed leukemia, myeloma, and chronic lymphocytic leukemia patients annually exceeds 100, 000 in China, we believe BEBT-908 has great potential as an anti-cancer drug. In addition to BEBT-908, the company has 3 new drug candidates for solid tumor treatment that have entered IND-enabling studies.

       The company's core innovation team was awarded as "Introduced Innovative and Entrepreneurial Team of Guangdong Province".
     The company's BEBT-908 clinical development project was selected as one of the prestigious "National Major Scientific and Technological Special Project for "Significant New Drugs Development"during the 13th Five-year Plan Period". The company is expected to complete phase III clinical trials of BEBT-908 for recurrent and refractory lymphoma, myeloma and CLL, and file NDAs in China in 3-5 years. Furthermore, we also planned to enter or complete phase II clinical trials for 2-3 new drug candidates for solid cancers in the 3-5 years.